ClinicalTrials.gg
Drug

17 alpha-Hydroxyprogesterone Caproate clinical trials

Also written Makena, 17P and Proluton depot.

studies test it
20
open now
1
in phase 3
10
first study started
2004

How each study uses 17 alpha-Hydroxyprogesterone Caproate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the 17 alpha-Hydroxyprogesterone Caproate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
26 Dec 1974 · HYDROXYPROGESTERONE CAPROATE · NDA 017439 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
2
Makena SQ
2
17-alpha hydroxyprogesterone caproate
2
170HP
2
Active Comparator
2

Brand

Makena
5
Proluton depot
2

Other names

17P
4
17-OHPC
3
Hydroxyprogesterone Caproate
1

Studies by the year they started

20 studies that test it; most in 2016 (3)

Studies that test 17 alpha-Hydroxyprogesterone Caproate, by start year
YearStudies
20042
20062
20071
20091
20101
20112
20131
20163
20173
20181
20193

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
6
Phase 3
10
Phase 4
2
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 6 · Other 14

AMAG Pharmaceuticals, Inc. (3) · Assiut University (2) · The George Washington University Biostatistics Center (2) · Obstetrix Medical Group (2) · Aswan University Hospital (2) · University of South Florida (1) · University of North Carolina, Chapel Hill (1) · University of Modena and Reggio Emilia (1)

Often tested with

Tested in the same studies.

Progesterone (3) · Nafarelin (1) · Estradiol, estriol drug combination (1) · Utrogestan (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test 17 alpha-Hydroxyprogesterone Caproate.

Studies

Open first, then newest update. How each study uses 17 alpha-Hydroxyprogesterone Caproate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 20

Codes

What other systems call 17 alpha-Hydroxyprogesterone Caproate · ClinicalTrials.gg INT006787

  • MeSH (NLM) D00007771317 alpha-Hydroxyprogesterone CaproateConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 276F2O42F5HYDROXYPROGESTERONE CAPROATEConfirmed FDA, NLM, Wikidata
  • RxNorm 12488Confirmed FDA, Wikidata
  • Wikidata Q3792032hydroxyprogesterone caproateConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C960Hydroxyprogesterone CaproateOne source FDA
  • DrugBank DB06789One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.